Table 1.
Baseline patient clinical and tumor profiling characteristics
| Characteristics | No. (%) |
|---|---|
| Age | |
| Median (range) | 67 (29-88) |
| Sex | |
| Male | 58 (53%) |
| Female | 52 (47%) |
| Smoking status | |
| Current smoker | 29 (26%) |
| Former smoker | 70 (64%) |
| Never smoker | 11 (10%) |
| Stage (AJCC 7th edition) | |
| IIIA | 48 (44%) |
| IIIB | 62 (56%) |
| Histology | |
| Adenocarcinoma | 73 (66%) |
| Squamous cell carcinoma | 18 (16%) |
| Mixed adenosquamous | 12 (11%) |
| Other | 7 (6%) |
| Radiation dose (Gy) | |
| Median (range) | 60 (50.4 - 74) |
| Chemotherapy | |
| Yes | 104 (95%) |
| Concurrent | 83 (75%) |
| Sequential | 21 (19%) |
| No | 6 (5%) |
| MSK-IMPACT gene panel | |
| IMPACT-468 | 40 (36%) |
| IMPACT-410 | 55 (50%) |
| IMPACT-341 | 15 (14%) |
| IMPACT sample site | |
| Primary | 47 (43%) |
| Metastatic | 63 (57%) |
Abbreviations: AJCC = American Joint Committee On Cancer; MSK-IMPACT = Memorial Sloan Kettering-Integrated Mutational Profiling of Actionable Cancer Targets.